Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 4/2011

Open Access 01-08-2011

Pain Management in Patients with Cancer: Focus on Opioid Analgesics

Author: Wojciech Leppert

Published in: Current Pain and Headache Reports | Issue 4/2011

Login to get access

Abstract

Cancer pain is generally treated with pharmacological measures, relying on using opioids alone or in combination with adjuvant analgesics. Weak opioids are used for mild-to-moderate pain as monotherapy or in a combination with nonopioids. For patients with moderate-to-severe pain, strong opioids are recommended as initial therapy rather than beginning treatment with weak opioids. Adjunctive therapy plays an important role in the treatment of cancer pain not fully responsive to opioids administered alone (ie, neuropathic, bone, and visceral colicky pain). Supportive drugs should be used wisely to prevent and treat opioids’ adverse effects. Understanding the pharmacokinetics, pharmacodynamics, interactions, and cautions with commonly used opioids can help determine appropriate opioid selection for individual cancer patients.
Literature
1.
World Health Organization. Cancer pain relief and palliative care. Geneva: World Health Organization; 1996.
2.
Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Expert working group of the research network of the European association for palliative care: morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587–93.PubMedCrossRef
3.
Leppert W. Progress in pharmacological pain treatment with opioid analgesics (Polish). Wspolcz Onkol. 2009;13:66–73.
4.
Eidelman A, White T, Swarm RA. Interventional therapies for cancer pain management: important adjuvants to systemic analgesics. J Natl Compr Canc Netw. 2007;5:753–60.PubMed
5.
Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004;9:571–91.PubMedCrossRef
6.
Leppert W. The role of ketamine in the management of neuropathic cancer pain—a polish experience. Proceedings of the 3rd International Congress on Neuropathic pain, NeuPSIG, Athens (Greece), May 27—30, 2010, Ed. Christopher D. Wells. Medimond International Proceedings 2010, pp. 199–203.
7.
Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008;44:1105–15.PubMedCrossRef
8.
Leppert W, Mikolajczak P. Analgesic effects and assays of controlled-release tramadol and o-desmethyltramadol in cancer patients with pain. Curr Pharmaceut Biotechnol. 2011;12:306–12.CrossRef
9.
Dickman A. Tramadol: a review of this atypical opioid. Eur J Palliat Care. 2007;14:181–5.
10.
Stamer UM, Lehnen K, Höthker F, Bayerer B, Wolf S, Hoeft A, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003;105:231–8.PubMedCrossRef
11.
Stamer U, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and o-desmethyltramadol enantiomers in different CY2D6 genotypes. Clin Pharmacol Ther. 2007;82:41–7.PubMedCrossRef
12.
• Stamer U, Stuber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008;107:926–929. This case report demonstrated the risk of respiratory depression in patients with UM of CYP2D6 and renal impairment during tramadol therapy. PubMedCrossRef
13.
Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB. Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? J Am Med Dir Associ. 2005;6:265–9.CrossRef
14.
Davies MP. Tramadol. In: Davies MP, Glare P, Hardy J, editors. Opioids in cancer pain. Oxford: Oxford University Press; 2005. p. 69–82.
15.
Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep. 2009;61:978–92.PubMed
16.
Ammon S, Hofmann U, Griese EU, Gugeler N, Mikus G. Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999;48:317–22.PubMedCrossRef
17.
Leppert W. Dihydrocodeine as an analgesic for the treatment of moderate to severe chronic pain. Curr Drug Metab. 2010;11:494–506.PubMedCrossRef
18.
Rowell FJ, Seymour RA, Rawlins MD. Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. Eur J Clin Pharmacol. 1983;25:419–24.PubMedCrossRef
19.
Schmidt H, Vormfelde SV, Walchner-Bonjean M, et al. The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003;41:95–106.PubMed
20.
Webb JA, Rostami-Hodjegan A, Abdul-Manap R, Hofmann U, Mikus G, Kamali F. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. Br J Clin Pharmacol. 2001;52:35–43.PubMedCrossRef
21.
Leppert W, Majkowicz M. The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain. Int J Clin Pract. 2010;64:1681–7.PubMedCrossRef
22.
Lötsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M, et al. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther. 2006;79:35–48.PubMedCrossRef
23.
Vree TB, van Dongen RTM, Koopman-Kimenai PM. Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract. 2000;54:395–8.PubMed
24.
Vree TB, Verwey-van Wissen CP. Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos. 1992;13:445–60.PubMedCrossRef
25.
Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351:2827–31.PubMedCrossRef
26.
Kirchheiner J, Schmidt H, Tzetkov M, Keulen J-T, Lötsch J, Roots I, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7:257–65.PubMedCrossRef
27.
Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant—an ultra-rapid metabolizer. Pediatr Anesth. 2007;17:684–7.CrossRef
28.
• Madadi P, Ross CJD, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009;85:31–35. This study demonstrated the risk of respiratory depression in neonates during breastfeeding of mothers with UM of CYP2D6 treated with codeine. PubMedCrossRef
29.
Madadi P, Moretti M, Djokanovic N, Bozzo P, Nulman I, Ito S, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Phys. 2009;55:1077–8.
30.
•• Flemming K. The use of morphine to treat cancer-related pain: a synthesis of quantitative and qualitative research. J Pain Symptom Manage 2010;39:139–154. This study depicts social, contextual, and physical concerns held by patients, careers, and health care professionals in using morphine. The study used critical interpretive synthesis, which combines conventional systematic review with interpretative synthesis of qualitative research. PubMedCrossRef
31.
Gretton S, Riley J. Morphine metabolites: a review of their clinical effects. Eur J Palliat Care. 2008;15:110–4.
32.
Ridgway D, Sopata M, Burneckis A, Jespersen L, Andersen C. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. J Pain Symptom Manage. 2010;39:712–20.PubMedCrossRef
33.
• Ripamonti CI, Campa T, Fagnoni E, Brunelli C, Luzzani M, Maltoni M, De Conno F. on behalf of MERITO Study Group. Normal-release oral morphine starting dose in cancer patients with pain. Clin J Pain 2009;25:386–390. This paper clearly demonstrated the effectiveness of immediate-release morphine in the treatment of pain in opioid-naïve and strong opioid-naïve cancer patients. PubMedCrossRef
34.
Donnelly S, Davis MP, Walsh D, Naughton M. Morphine in cancer pain management: a practical guide. Support Care Cancer. 2002;10:13–25.PubMedCrossRef
35.
Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage. 1997;13:254–61.PubMedCrossRef
36.
Leppert W, Luczak J, Gorzelinska L, Kozikowska J. Research from the palliative care department in Poznań on treatment of neoplasm pain with durogesic (transdermal fentanyl) (Polish). Przegl Lek. 2000;57:59–64.PubMed
37.
Vielvoye-Kerkmeer APE, Mattern C, Uitendaal MP. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manage. 2000;19:185–92.PubMedCrossRef
38.
Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2008;5:327–34.
39.
Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage. 1996;12:182–9.PubMedCrossRef
40.
Leppert W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep. 2010;62:578–91.PubMed
41.
Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, et al. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology. 2009;110:1371–8.PubMedCrossRef
42.
Likar R, Krainer B, Sittl R. Challenging the equipotency calculation for transdermal buprenorphine: four case studies. Int J Clin Pract. 2008;62:152–6.PubMedCrossRef
43.
Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer. 2007;15:441–4.PubMedCrossRef
44.
• Kress HG. Clinical update on he pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009; 13:219–230. This is a comprehensive review of pharmacology and clinical application of buprenorphine in patients with chronic pain. PubMedCrossRef
45.
Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001;9:84–96.PubMedCrossRef
46.
Wirz S, Wartenberg HC, Nadstawek J. Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. Support Care Cancer. 2008;16:999–1009.PubMedCrossRef
47.
Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol. 1998;16:3216–21.PubMed
48.
Leppert W. The role of methadone in cancer pain treatment—a review. Int J Clin Pract. 2009;63:1095–109.PubMedCrossRef
49.
Tzschentke TM, Christoph T, Kögel B, et al. (−)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265–76.PubMedCrossRef
50.
Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metabol Lett. 2008;2:67–75.CrossRef
51.
•• Lötsch J, Geisslinger G, Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 2009;124:168–184. This paper discusses a possible influence of different genetic disposition of patients to respond to analgesics. PubMedCrossRef
Metadata
Title
Pain Management in Patients with Cancer: Focus on Opioid Analgesics
Author
Wojciech Leppert
Publication date
01-08-2011
Publisher
Current Science Inc.
Published in
Current Pain and Headache Reports / Issue 4/2011
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-011-0201-7

Other articles of this Issue 4/2011

Current Pain and Headache Reports 4/2011 Go to the issue

ReviewPaper

Headache and Neck

ReviewPaper

Unusual Headaches in the Elderly

ReviewPaper

Psychosocial Issues in Cancer Pain

ReviewPaper

Headache Attributable to Nonvascular Intracranial Disorders

Invited Commentary

Epidemiology of Cancer Pain

Clinical Trial Report

Designing Studies for Cluster Headache: Lessons Learned